Third Quarter 2020 Results
Bayer AG News Conference Call
Challenging third quarter – Group outlook confirmed
- Group sales decrease by 5.1 percent (Fx & portfolio adj.) to 8.506 billion euros
- EBITDA before special items falls 21.4 percent to 1.795 billion euros
- Substantial decline in sales and earnings at Crop Science, heavily impacted by seasonal and currency effects
- Pharmaceuticals business recovering – higher earnings but slightly lower sales
- Strong performance at Consumer Health
- Net loss of 2.744 billion euros – impairment charges at Crop Science, proceeds from divestment of Animal Health
- Core earnings per share decline by 30.2 percent to 0.81 euros
- Free cash flow falls by 2.1 percent to 1.237 billion euros
Statement in written form and presentation slides
Recording (dubbed into English):
Audio: Webcast of the speech with presentation slides (part 1)
Audio: Webcast of the speech with presentation slides (part 2)
Audio: MP3 of the speech for download (part 1; MP3, 7.2 MB, 7:41 min.)
Audio: MP3 of the speech for download (part 2; MP3, 3 MB, 3:16 min.)
Recording (dubbed into English):
Audio: Webcast with presentation slides
Audio: MP3 of the discussion for download (MP3, 41.6 MB, 44:24 min.)
